Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.

Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB.

Parkinsonism Relat Disord. 2013 Jul;19(7):670-5. doi: 10.1016/j.parkreldis.2013.03.003. Epub 2013 Apr 2.

PMID:
23561946
2.

Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.

Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E.

J Clin Psychiatry. 2001 Jun;62(6):453-63.

PMID:
11465523
3.

Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.

Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T.

Sleep. 2010 Nov;33(11):1553-61.

4.

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.

Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A.

Sleep. 2007 Nov;30(11):1555-61.

5.

Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease.

Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P; ELEP Group.

Parkinsonism Relat Disord. 2013 Dec;19(12):1152-5. doi: 10.1016/j.parkreldis.2013.07.026. Epub 2013 Aug 15.

PMID:
23953775
6.

Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.

Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T.

Sleep Med. 2012 Feb;13(2):133-8. doi: 10.1016/j.sleep.2011.09.006. Epub 2011 Dec 24.

PMID:
22197474
7.

Low-dose doxepin for the treatment of insomnia: emerging data.

Goforth HW.

Expert Opin Pharmacother. 2009 Jul;10(10):1649-55. doi: 10.1517/14656560903005587. Review.

PMID:
19496739
8.

Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial.

Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS.

J Clin Oncol. 2014 Feb 10;32(5):449-57. doi: 10.1200/JCO.2012.47.7265. Epub 2014 Jan 6.

PMID:
24395850
9.

The efficacy of Cognitive-Behavioural Therapy (CBT) as related to sleep quality and hyperarousal level in the treatment of primary insomnia.

Gałuszko-Węgielnik M, Jakuszkowiak-Wojten K, Wiglusz MS, Cubała WJ, Landowski J.

Psychiatr Danub. 2012 Sep;24 Suppl 1:S51-5.

10.

Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial.

Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D.

J Sleep Res. 2012 Dec;21(6):700-9. doi: 10.1111/j.1365-2869.2012.01021.x. Epub 2012 May 22.

11.

Self-help treatment for insomnia symptoms associated with chronic conditions in older adults: a randomized controlled trial.

Morgan K, Gregory P, Tomeny M, David BM, Gascoigne C.

J Am Geriatr Soc. 2012 Oct;60(10):1803-10. doi: 10.1111/j.1532-5415.2012.04175.x. Epub 2012 Oct 4.

PMID:
23035962
12.

Randomized Controlled Pilot Trial of Behavioral Insomnia Treatment for Chronic Migraine With Comorbid Insomnia.

Smitherman TA, Walters AB, Davis RE, Ambrose CE, Roland M, Houle TT, Rains JC.

Headache. 2016 Feb;56(2):276-91. doi: 10.1111/head.12760. Epub 2016 Jan 27.

PMID:
26813845
13.

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.

Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, Ereshefsky L, Lankford A, Roth T.

J Clin Psychiatry. 2008 Oct;69(10):1557-64. Epub 2008 Oct 7.

PMID:
19192438
14.

Internight sleep variability: its clinical significance and responsiveness to treatment in primary and comorbid insomnia.

Sánchez-Ortuño MM, Edinger JD.

J Sleep Res. 2012 Oct;21(5):527-34. doi: 10.1111/j.1365-2869.2012.01010.x. Epub 2012 Mar 30.

15.

Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial.

Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC.

JAMA Neurol. 2017 Apr 1;74(4):411-418. doi: 10.1001/jamaneurol.2016.5192.

PMID:
28241159
16.

Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia.

Hajak G, Rodenbeck A, Adler L, Huether G, Bandelow B, Herrendorf G, Staedt J, Rüther E.

Pharmacopsychiatry. 1996 Sep;29(5):187-92.

PMID:
8895944
17.
18.

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.

Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, Wu SS, Pillarisetty S, Nyathappa A, Eisenschenk S.

Int J Neurosci. 2009;119(12):2196-205. doi: 10.3109/00207450903222758.

PMID:
19916848
19.

I-CAN SLEEP: rationale and design of a non-inferiority RCT of Mindfulness-based Stress Reduction and Cognitive Behavioral Therapy for the treatment of Insomnia in CANcer survivors.

Garland SN, Carlson LE, Antle MC, Samuels C, Campbell T.

Contemp Clin Trials. 2011 Sep;32(5):747-54. doi: 10.1016/j.cct.2011.05.014. Epub 2011 Jun 1.

PMID:
21658476
20.

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.

Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.

J Clin Psychiatry. 2011 Jul;72(7):914-28. doi: 10.4088/JCP.09m05571gry. Epub 2010 Dec 28.

PMID:
21208597

Supplemental Content

Support Center